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Abstract 21 
Osteomyelitis is an inflammatory process of bone and bone marrow that may even lead to patient 22 
death. Even though this disease is mainly caused by Gram-positive organisms, the proportion of 23 
bone infections caused by Gram-negative bacteria, such as Escherichia coli, has significantly 24 
increased in recent years. In this work, mesoporous silica nanoparticles have been employed as a 25 
platform to engineer a nanomedicine able to eradicate E. coli- related bone infections. For that 26 
purpose, the nanoparticles have been loaded with moxifloxacin and further functionalized with 27 
Arabic gum and colistin (AG+CO-coated MX-loaded MSNs). The nanosystem demonstrated high 28 
affinity toward E. coli biofilm matrix, thanks to AG coating, and marked antibacterial effect 29 
because of the bactericidal effect of moxifloxacin and the disaggregating effect of colistin. 30 
AG+CO-coated MX-loaded MSNs were able to eradicate the infection developed on a trabecular 31 
bone in vitro and showed pronounced antibacterial efficacy in vivo against an osteomyelitis 32 
provoked by E. coli. Furthermore, AG+CO-coated MX-loaded MSNs were shown to be 33 
essentially non-cytotoxic with only slight effect on cell proliferation and mild hepatotoxicity, 34 
which might be attributed to the nature of both antibiotics. In view of these results, these 35 
nanoparticles may be considered as a promising treatment for bone infections caused by 36 
enterobacteria, such as E. coli, and introduce a general strategy against bone infections based on 37 
the implementation of antibiotics with different but complementary activity into a single 38 
nanocarrier. 39 
Keys words: osteomyelitis, Escherichia coli, biofilm, nanoparticles, Arabic gum, colistin, 40 
moxifloxacin  41 
Abbreviations 42 
AG: Arabic gum 43 
AG+CO: Arabic gum containing colistin 44 
APTES: 3-(aminopropyl)triethoxysilane 45 
BHI: brain-heart infusion 46 
CAMHB: cation adjusted Müller-Hinton broth 47 
CFU: colony-forming unit 48 
CO-FITC: Colistin labelled with fluorescein isothiocyanate 49 
CO: colistin 50 
CTAB: cetyltrimethylammonium bromide 51 
Cyp3A: cytochrome P450 3A4 52 
DLS: dynamic Light Scattering 53 
DMSO: dimethyl sulfoxide 54 
FTIR: Fourier Transformed Infrared 55 
GFP: green fluorescent protein 56 
HBSS: Hanks’ balanced saline solution 57 
Hs: hepatocytes 58 
IL-6: interleukine 6 59 
KCs: Kupffer cells 60 
MBC: minimum bactericidal concentration 61 
MBEC: minimum biofilm eradication concentration 62 
MBIC: minimum biofilm inhibitory concentration 63 
MIC: minimum inhibitory concentration 64 
MSNs: mesoporous silica nanoparticles 65 
MX: RhB moxifloxacin 66 
NPCs: non-parenchymal cells 67 
PBS: phosphate buffer saline 68 
PI: propidium iodide 69 
RANKL: receptor activator for nuclear factor κ B Ligand 70 
RhB: Rhodamine B isothiocyanate 71 
SEM: scanning electron microscopy 72 
TEOS: tetraethyl orthosilicate 73 
TGA: thermogravimetric Analysis 74 
TNF-α: tumour necrosis factor α 75 
TVX: trovafloxacin 76 
1. Introduction 77 
Osteomyelitis is an inflammatory process of bone and bone marrow caused by at least one 78 
microorganism, which causes local bone destruction, necrosis, and apposition of new bone and 79 
can compromise bone or joint infection [1]. Despite its incidence is almost 22 cases per 100,000 80 
person-years [2], the implications of this disease are beyond these numbers, including mortality. 81 
Although osteomyelitis can be virtually caused by any microorganism, bone infections are mainly 82 
caused by Gram-positive bacteria, such as Staphylococcus aureus, which is responsible for up to 83 
90% of the cases of pyogenic osteomyelitis [1]. However, the proportion of bone infections 84 
caused by Gram-negative bacteria has significantly increased over the last few years [4,5]. Among 85 
them, enterobacteria, like Escherichia coli, have attracted much attention owing to their ability to 86 
reach antibiotic multi-resistance [6,7]. Besides, the bacterial pathogeny of this infection involves 87 
the biofilm development, which is a growth form increases the resistance to multiple adverse 88 
situations, including phagocytosis by phagocytic cells from immune systems, as well as 89 
antibiotics [8]. For this reason, the most frequent treatments for osteomyelitis include intravenous 90 
antibiotic administration together with surgical removal of portions of infected or dead bone 91 
[9,10]. 92 
In the last few decades, the application of nanotechnology to medicine, so-called nanomedicine, 93 
has attracted much attention and it is expected to revolutionize the biotechnological and 94 
pharmaceutical industries shortly. In this regard, nanoparticles acting as drug delivery vehicles 95 
account for 75% of the market share of approved nanomedicines [11]. Among the different types 96 
of nanocarriers, mesoporous silica nanoparticles (MSNs) are considered as promising candidates 97 
for drug delivery owing to features, such as large surface areas (ca. 1000 m2/g) and pore volumes 98 
(ca. 1 cm3/g), tunable pore size and morphologies, ease of surface modification, and 99 
biocompatibility [12–15]. As a result, MSNs have been widely applied to treat several diseases, 100 
including complex bone diseases, such as osteoporosis, bone cancer and bone infection [16]. 101 
Regarding the latter, the suitability of loading MSNs with low-molecular-weight antibiotics for 102 
eliminating E. coli bone infections has been reported [17–19]. Aside from treating bone 103 
infections, endowing the nanoparticles with ability to recognize infection is of major importance. 104 
In this regard, some authors have reported the use of antibodies, aptamers, dendrimers, or proteins, 105 
among others, to target bone infection [20].  106 
In this work, we have employed MSNs to engineer a drug delivery nanovehicle for the potential 107 
treatment of bone infection (Scheme 1). Because of the potential translation of this nanomaterial, 108 
two clinically relevant antibiotics, moxifloxacin (MX) and colistin (CO), were selected as 109 
payloads. MX is a fourth-generation fluoroquinolone antibacterial agent with a broad spectrum 110 
of activity, encompassing Gram-negative and Gram-positive bacteria [21], that has been used in 111 
monotherapy in bone-related infection [22–24]. CO is a polymyxin agent (polymyxin E) that has 112 
proven to be effective against Gram-negative infections [25], and was selected because of its anti-113 
E. coli ability vouched by previous in vitro and in vivo studies of prosthetic joint infection [26]. 114 
Given the pivotal role of biofilm formation during this type of infection, we aimed to endow 115 
MSNs with selectivity for the E. coli biofilm model to enhance the efficacy of the treatment. For 116 
that purpose, the surface of nanoparticles was modified with Arabic gum (AG), a branched-chain, 117 
complex polysaccharide composed of 1,3-linked beta-D-galactopyranosyl monomers connected 118 
to the main chain through 1,6-linkages [27], whose degradation by secreted bacterial enzymes 119 
was observed to improve the retention of MSNs on the biofilm. Furthermore, it was observed that 120 
the use of the AG coating improved the adsorption of CO on the surface of MSNs. Finally, the 121 
bactericidal effect of this biocompatible nanocarrier was extensively analysed in vitro and in vivo, 122 
showing promising results. To the best of our knowledge, this is the first time that MSNs are 123 
engineered to carry low molecular weight and a high molecular weight antibiotic at the same time, 124 
instead of just one antibiotic, while achieving significant targeting capacity for E. coli biofilm and 125 
substantial efficacy in vivo.   126 
2. Materials and Methods 127 
 128 
2.1. Synthesis of MCM-41 mesoporous silica nanoparticles 129 
The following compounds were purchased from Sigma-Aldrich (USA): Tetraethyl orthosilicate 130 
(TEOS); Ammonium nitrate; Cetyltrimethylammonium bromide (CTAB); Rhodamine B 131 
isothiocyanate (RhB); 3-(Aminopropyl)triethoxysilane (APTES). 132 
Mesoporous silica nanoparticles were synthesized through a modification of the Stöber method 133 
[28]. For that purpose, H2O (480 mL), NaOH (2 M, 3.5 mL) and CTAB (2.74 mmol, 1 g), were 134 
mixed in a 1-L flask and heated to 80ºC. Then, TEOS (22.39 mmol, 5 mL) was added dropwise 135 
(0.33 mL/min) over 15 minutes and the whole mixture was then stirred at 80ºC for 2 h. After that, 136 
the nanoparticles were collected by centrifugation and washed twice with water and once with 137 
ethanol. The organic template was removed by ionic exchange, using a solution of NH4NO3 (10 138 
mg/mL) in ethanol (95%). For that purpose, nanoparticles were dispersed in 350 mL of such 139 
solution, refluxed for 3 h and subsequently centrifuged and washed with water and ethanol. The 140 
whole process was repeated two times, and the final surfactant-free nanoparticles were stored in 141 
absolute ethanol. 142 
The biological experiments were performed using Rhodamine B-labelled MSNs. For this end, 143 
RhB (0.002 mmol, 1.07 mg) was reacted with APTES (0.009 mmol, 2.2 µL) in 40 µL of ethanol 144 
for 2 h. Then, this mixture was gently mixed with TEOS (22.39 mmol, 5 mL) and the synthesis 145 
of MSNs was carried out as described above. 146 
The nanoparticles were characterized in terms of Fourier Transformed Infrared (FTIR) 147 
spectroscopy, Thermogravimetric Analysis (TGA), Dynamic Light Scattering (DLS), Zeta 148 
potential, and N2 adsorption analysis. FTIR spectra were collected in a Nicolet Nexus (Thermo 149 
Fisher Scientific) equipped with a Goldengate attenuated total reflectance device, averaging 64 150 
scans in the range 4000-400 cm-1 (resolution 1 cm-1). TGA measurements were carried out in a 151 
Perkin Elmer Pyris Diamond TG/DTA analyser, applying 5ºC/min heating ramps from rt to 152 
600ºC. DLS and Zeta potential measurements were performed in a Zetasizer Nano ZS (Malvern 153 
Instruments) equipped with a 633 nm laser. Samples were dispersed in distilled water with 154 
sonication and placed in a DTS1070 disposable folded capillary cell (Malvern instruments) for 155 
data acquisition. N2 adsorption analysis (adsorption and desorption isotherms) were obtained in a 156 
Micromeritics ASAP 2020. Samples were degassed under vacuum for 24 hours and analyzed at 157 
77 K. Pore size was estimated from the maximum of the pore size distribution plot.  158 
2.2. Arabic gum coating of nanoparticles and antibiotic release from coated 159 
nanoparticles 160 
Arabic gum coating was performed by adapting a methodology previously described [29]. The 161 
use of Arabic gum is based on the enterobacterial ability to degrade and use it as carbon source 162 
[30,31]. MSNs were initially functionalized with AG before the antibiotics incorporation to find 163 
out the conditions that provided significant AG deposition onto the surface. Briefly, Arabic gum 164 
(10%, w/v) was prepared by dissolving 4 g of Arabic gum from acacia tree powder (Sigma 165 
Aldrich, USA) in 20 mL distilled water. The solution was stirred with low heat (40-45 ◦C) for 60 166 
min using a hot plate magnetic stirrer and was left to cool down to room temperature. Then, 1 mL 167 
of Arabic gum 10% was deposited in a 4-mL glass recipient under vigorous agitation at room 168 
temperature and mixed with 1 mL of water with 12 mg/mL of MSNs for 10 min. Then, the 169 
nanoparticles were centrifuged and washed twice with distilled water, leading to AG-coated 170 
MSNs. 171 
For the synthesis of Arabic gum plus colistin-coated MSNs, 50 mg of colistin sodium 172 
methanesulfonate (Sigma Aldrich, USA) were mixed with 1 mL of Arabic gum 10% and the 173 
coating was carried out as described above to yield AG+CO-coated MSNs. 174 
The coated nanoparticles were characterized in terms of Fourier Transformed Infrared (FTIR) 175 
spectroscopy, Thermogravimetric Analysis (TGA), Transmission Electron Microscopy (TEM), 176 
Dynamic Light Scattering (DLS) and Zeta potential.   TEM images were taken on a JEOL JEM 177 
1400. Samples were dispersed in distilled water under sonication and then few drops were 178 
deposited onto carbon-coated copper grids.  179 
2.3. Antibiotic loading into the nanoparticle and antibiotic release 180 
One millilitre of a 5 mg/mL solution of moxifloxacin (Sigma Aldrich, USA) (MX) in HEPES 181 
buffer [32] (Lonza, Switzerland) was added to 12 mg of MSNs. These MSNs were loaded at 500 182 
rpm and 5ºC for 24 h [33]. After loading, MSNs were washed two times with HEPES buffer (MX-183 
loaded MSNs).  184 
To determine the moxifloxacin release from loaded MSNs, 12 mg of MSNs were suspended in 1 185 
mL of phosphate buffer saline (PBS) (pH=7.4) (Lonza, Switzerland). This suspension was placed 186 
with another millilitre of PBS into the lower chamber from a Transwell® 6-well plate (Corning, 187 
USA). Then, the upper chamber of the Transwell® 6-well plate was placed and 1 mL of PBS was 188 
added. This buffer was selected because is one of the most used buffer for antibiotic release [34–189 
38]. The final concentration of nanoparticles was 4 mg/mL per well (n=4). The plate was 190 
incubated at 37ºC and 5% CO2. Periodically, 300 µL of each upper chamber from well were 191 
sampled and replaced by 300 µL of new PBS. These 300 µL were used to determine moxifloxacin 192 
concentration by measuring the fluorescence using an excitation wavelength of 294 nm and an 193 
emission wavelength of 503 nm [39], and a calibration curve made with a concentration range 194 
from 125 to 0.122 μg/mL. This experiment was performed four times. 195 
To determine the colistin release from Arabic gum plus colistin coated MSNs, 12 mg of MSNs 196 
were coated with 50 mg of colistin in presence or absence of 1 mL of Arabic gum 20%. Colistin 197 
previously labelled with fluorescein isothiocianate (CO-FITC) to monitor the release. For that 198 
reason, 50 mg of colistin and 0.1 mg of FITC were dissolved in DMSO and stirred overnight at 199 
RT. The mixture was then precipitated in cold ether/acetone (90:10), centrifuged and washed with 200 
ethanol until no FITC was observed in the supernatant. CO-FITC MSNs were suspended in 1 mL 201 
of phosphate buffer saline (PBS) (Lonza, Switzerland) to evaluate the release kinetics. This 202 
millilitre was placed with another millilitre of PBS into the lower chamber from a Transwell® 6-203 
well plate (Corning, USA). Then, the upper chamber of the Transwell® 6-well plate was placed 204 
and 1 mL of PBS was added. The final concentration of nanoparticles was 4 mg/mL per well 205 
(n=3). The plate was incubated at 37ºC and 5% CO2. Regularly, 300 µL of each upper chamber 206 
from well were sampled and replaced by 300 µL of new PBS. These 300 µL were used to 207 
determine colistin-FITC concentration by measuring the fluorescence using an excitation 208 
wavelength of 490 nm and an emission wavelength of 525 nm, and a calibration curve made with 209 
a concentration range from 500 to 0.244 μg/mL. 210 
2.4. Microbiological studies 211 
E. coli ATCC 25922-GFP strain was used in all microbiological studies. This strain can produce 212 
a green fluorescent protein (GFP). The strain was kept frozen at ‒80 °C until experiments were 213 
performed. According to the recommendations of the commercial house, this strain was grown in 214 
tryptic soy broth (BioMérieux, France) supplemented with 100 µg/mL of ampicillin (Merck, 215 
USA) at 37 °C in 5 % CO2. The purity of its axenic culture was corroborated every day by 216 
inoculating each broth on a blood tryptic-soy agar (BioMérieux, France). 217 
2.4.1. Bacteria-nanoparticle interaction 218 
The E. coli-nanoparticle interaction was evaluated by using four different experiments, (1) use of 219 
Arabic gum coating as a carbon source by E. coli, (2) E. coli biofilm-nanoparticles interaction, 220 
(3) bactericidal ability of Arabic gum plus colistin coating against E. coli and, (4) E. coli effect 221 
on the release of drugs loaded in the nanoparticles. 222 
To evaluate the use of Arabic gum coating as a carbon source by E. coli, 500 µL of PBS with 10 223 
mg/mL (1% p/v) of each type of nanoparticle (MSNs and AG-coated MSNs) were deposited in a 224 
well from a 24-well plate. Then, 10 µL of a bacterial suspension with 3.18×106 CFU/mL were 225 
added. PBS supplemented with 1% of Arabic gum was used as positive control. Then, the plate 226 
was incubated statically at 37°C and 5% CO2 for 24 h. After incubation, 300 µL of each well were 227 
placed in a 96-well flat-bottom plate (Thermo Fisher Scientific, USA) and their fluorescence was 228 
measured using an excitation wavelength of 488 nm and an emission wavelength of 510 nm. This 229 
experiment was performed by duplicate and four times (n=8 per condition). 230 
To describe the E. coli effect on the release of drugs loaded in AG-coated MSNs, 12 mg of MSNs 231 
were loaded with 500 µL of propidium iodide (PI) in water (500 µg/mL) (Sigma Aldrich, USA) 232 
at 750 rpm and 5ºC for 24 h. After loading, these nanoparticles were rinsed one time with 1 mL 233 
of distilled water. After this, 12 mg of each PI-loaded MSNs were suspended in 1 mL of brain-234 
heart infusion (BHI) (BD, USA) to determine the PI release from AG-coated PI-loaded and 235 
noncoated PI-loaded MSNs. This suspension was mixed 1:1 with another suspension (108 236 
CFU/mL of bacteria in BHI) into the lower chamber from a Transwell® 6-well plate. Then, the 237 
upper chamber of the Transwell® 6-well plate was inserted and 1 mL of BHI was added. The 238 
final concentration of nanoparticles was 4 mg/mL per well. The plate was incubated at 37ºC and 239 
5% CO2. Periodically, 300 µL of each upper chamber from well were sampled and replaced by 240 
300 µL of sterile BHI. These 300 µL were used to determine the PI concentration by measuring 241 
the fluorescence using an excitation wavelength of 493 nm and an emission wavelength of 636 242 
nm, and a calibration curve made with a concentration range from 250 to 0.122 μg/mL. The 243 
bacterial concentration was estimated by using a well from a 6-well plate with the same bacterial 244 
concentration but without MSNs. This experiment was performed by triplicate. 245 
To study E. coli biofilm-nanoparticles interaction, 100 µL of saline 0.9% NaCl (B. Braun, 246 
Germany) with 3.23×108 CFU/mL were placed in each well of a 96-well flat-bottom plate and 247 
incubated statically at 37°C and 5% CO2 for 1.5 h. The supernatant was then removed, and each 248 
well was rinsed two times with 150 µL of saline. Then, 200 µL of wound-like medium were added 249 
to each well, and the plate was incubated statically at 37°C and 5% CO2 for 48 h. Wound-like 250 
medium is composed by 5 mL of Bolton broth (Sigma Aldrich, USA), 4.5 mL of bovine adult 251 
serum (Sigma Aldrich, USA), and 0.5 mL of laked horse blood (Oxoid, USA) [40,41].  The use 252 
of wound-like medium had no other purpose but mimicking in vitro the nutritional conditions that 253 
a bacterium causing bone infection could find in vivo. After incubation, the supernatant was 254 
removed, and each well was rinsed two times with 200 µL of saline. Then, 150 µL of saline with 255 
2 mg/mL of each type of MSN (MSN, AG-coated MSN, and AG+CO-coated MSNs) were added 256 
to the corresponding wells and incubated at 100 rpm, 37°C, and 5% CO2 for 30 min and 3 h. After 257 
that, each well was rinsed again with 200 µL of saline and stained with 1% of safranin, according 258 
to a previously reported methodology [42]. The experiment was performed by triplicate (n=24 259 
per condition). 260 
To demonstrate the bactericidal ability of Arabic gum plus colistin coating against E. coli, 500 261 
µL of saline with 1×108 CFU/mL plus 500 µL of saline with 4 mg/mL of each type of nanoparticle 262 
(MSNs, AG-coated MSNs, and AG+CO-coated MSNs) were placed in a 2-mL tube (final 263 
concentration of 2 mg/mL). This concentration of bacteria was chosen to bring to light the 264 
antibacterial effect of MSNs without needing the bacterial growth. Each tube was agitated at 1.400 265 
rpm and 37ºC for 30 min. After this, 150 µL of each tube were mixed with 150 µL of tryptic-soy 266 
broth supplemented with 20% alamarBlue (BIO-RAD, USA) [43] in a well from a 96-well flat-267 
bottom plate, and were incubated at 100 rpm and 37ºC for  2 h. The fluorescence from each well 268 
was then measured using an excitation wavelength of 560 nm and an emission wavelength of 590 269 
nm. This experiment was performed four times (n=4 per condition). To support visually the 270 
numerical results, the previous experiment was analysed using transmission electron microscopy 271 
(TEM). The protocol for TEM has been described previously [44]. Semithin sections (0.6 μm) for 272 
light microscopy and thin sections (60 nm) for TEM of resin-included bacteria were cut using a 273 
Leica Ultracut ultramicrotome UC7 (Leica). Sections were collected on 200 mesh nickel grids 274 
and examined using a Jeol JEM 1400 transmission electron microscope (Jeol Ltd, Tokyo, Japan). 275 
2.4.2. Minimal inhibitory concentration and minimal bactericidal concentration 276 
Minimum inhibitory concentrations (MIC) were determined using the previously described broth 277 
microdilution method [45] with one modification. The MIC is the minimum concentration 278 
required to inhibit the bacterial visible growth. The main modification consisted of supplementing 279 
all the broth used with 100 µg/mL of ampicillin. In brief, a series of nanoparticle concentrations 280 
starting from 2,000 µg/mL to 1.953 µg/mL with a two-fold dilution were added to cation adjusted 281 
Müller-Hinton broth (Sigma Aldrich, USA) (CAMHB) to a final volume of 100 μL per well. One 282 
hundred microlitres of bacterial suspension in CAMHB containing approximately 1.6×106 283 
colony-forming units per millilitre (CFU/mL) was added to a Costar 96-well round-bottom 284 
polypropylene plate (Corning Inc., USA) followed by static incubation at 37°C and 5% CO2 for 285 
at least 20 h. After incubation, MIC was determined measuring fluorescence using an excitation 286 
wavelength of 488 nm and an emission wavelength of 510 nm. Minimum bactericidal 287 
concentration (MBC) were determined using the flash microbiocide method previously described 288 
[27]. The MBC is defined as the minimum concentration required to kill a certain bacterial 289 
concentration. Briefly, 10 μL of each well were mixed after 24-h incubation with 190 μL of tryptic 290 
soy broth in a new 96-well plate, which was further incubated statically at 37°C and 5% CO2 for 291 
24 h. After incubation, MBC was determined by measuring the fluorescence, using an excitation 292 
wavelength of 488 nm and an emission wavelength of 510 nm. The experiments were performed 293 
by triplicate. 294 
2.4.3. Minimal biofilm inhibitory concentration and minimal biofilm eradication 295 
concentration 296 
Minimal biofilm inhibitory concentrations (MBIC) and minimal biofilm eradication 297 
concentrations were determined using the methodology previously described [47]. The MBIC is 298 
the minimum concentration required to inhibit the visible growth of a bacterial biofilm. For 299 
MBIC, biofilm formation on pegs from the Calgary device was induced by inoculating 200 µL of 300 
tryptic-soy broth containing 106 CFU/mL of bacteria per well in a 96-well flat-bottom plate 301 
(Thermo Fisher Scientific, Massachusetts, United States). The lid (Thermo Fisher Scientific) of 302 
the Calgary device was then placed and the plate was incubated in turmoil at 37°C and 5% CO2 303 
for 24 h.  After incubation, the pegs from the lid were rinsed two times in wells containing 200 304 
µL of saline. Afterwards, the lid was placed in a plate with different MSN concentrations starting 305 
from 2 mg/mL to 1.953 µg/mL with a two-fold dilution were added to CAMHB to a final volume 306 
of 200 μL per well and was incubated by static incubation at 37°C and 5% CO2 for at least 20 h. 307 
After incubation, MBIC was determined by measuring the fluorescence, using an excitation 308 
wavelength of 488 nm and an emission wavelength of 510 nm. The MBEC is the minimum 309 
concentration required to kill a bacterial biofilm. For MBEC, the lid from the MBIC was rinsed 310 
two times in a plate with wells containing 200 µL of saline 0.9% NaCl, placed in a plate with 200 311 
µL of tryptic-soy broth, and incubated statically at 37°C and 5% CO2 for 24 h. After incubation, 312 
MBEC was determined by measuring the fluorescence, using an excitation wavelength of 488 nm 313 
and an emission wavelength of 510 nm. The experiments were performed by triplicate. 314 
2.4.4. Anti-biofilm efficacy of AG+CO-coated MX-loaded MSNs 315 
A four-mL flat-bottom sterile tube with 25 mg of bovine trabecular bone (Bio-Oss Spongiosa 316 
from 0.25 to 1mm; Inibsa, Spain) was rinsed with 1 mL of saline. Then, 500 µL of saline with 317 
3.15×108 CFU/mL were added to each tube and were incubated statically at 37°C and 5% CO2 318 
for 1.5 h. The supernatant was then removed, and each tube was rinsed two times with 1 mL of 319 
saline. Afterward, 1 mL of wound-like medium were placed into each tube, which were further 320 
incubated statically at 37°C and 5% CO2 for 48 h. The wound-like medium is a biofilm model 321 
that resembles  the type of biofilm that is usually found in clinical practice [48]. The rationale for 322 
using this medium relies on its composition. Among others, this wound-like medium contains 323 
erythrocytes and serum, which are components that the nanoparticles would have to deal with in 324 
an infection in a human body. Hence, the purpose of using bovine trabecular bone and wound-325 
like medium was to mimic in vitro in a very realistic way the conditions where a bacterium 326 
causing osteomyelitis would grow in vivo. After biofilm formation, each tube was rinsed two 327 
times with 1 mL saline and treated in presence or absence of 1 mL of two effective concentrations 328 
of nanoparticles, which were further incubated statically at 37°C and 5% CO2 for 24 h. Such 329 
concentrations, 31.25 and 62.5 µg/mL, were estimated according to the MBEC obtained, and 330 
considering previous studies that stablish 4 × MIC as a good therapeutic approach [32,49]. After 331 
incubation, each tube was rinsed two times with 1 mL of saline and all trabecular bone from each 332 
tube were transferred to a 5 mL round-bottom tube containing 1 mL of saline. All tubes were 333 
sonicated at room temperature for 5 min [50].  Then, the number of bacteria was determined as 334 
CFU per gram of bone by using the drop plate method [51] in MacConkey agar plates 335 
(BioMérieux, France). The plates were incubated at 37°C and 5% CO2 at least 24 h. The 336 
experiment was performed five times. 337 
To support visually the numerical results, the previous experiment was analysed using laser 338 
confocal microscopy and scanning electron microscopy (SEM). For laser confocal microscopy, 339 
the experiment was performed in a 4×2 glass-bottom plate (ibidi, Germany) where the tubes were 340 
replaced by wells, and all the above-mentioned volumes were replaced by 300 µL of each 341 
medium. After 24 h, each well was directly analysed in a Leica DM IRB confocal laser-scanning 342 
microscope (Leica, Germany) without removing the supernatant. For SEM study, the same 343 
samples were fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer at pH 7 at 4º C 344 
for 90 min. Samples were then dehydrated with increasing concentrations of ethanol (30, 50, 70, 345 
90, and 100%) at 22ºC for 10 min. Micrographs were obtained using a field emission gun JEOL 346 
JSM6400 scanning electron microscope (Jeol Ltd, Tokyo, Japan). 347 
2.5. Cell studies 348 
MC3T3-E1 cells were inoculated in a concentration of 10,000 cells/cm2 on 96-well plates with α-349 
minimum essential medium with 10 % foetal bovine serum and 1% penicillin-streptomycin 350 
(αMEM, Invitrogen, Thermo Fisher Scientific). RAW264.7 cells were seeded in a concentration 351 
of 5,000 cells/cm2 on 96-well plates with α-minimum essential medium with 10 % foetal bovine 352 
serum and 1% penicillin-streptomycin (αMEM, Invitrogen, Thermo Fisher Scientific Inc. USA). 353 
After cell adherence, MC3T3-E1 cells medium was replaced by αMEM with 50 mg/mL ascorbic 354 
acid (Sigma-Aldrich, USA), 10 mM ß-glycerol-2-phosphate (Sigma-Aldrich, USA), and part of 355 
the RAW264.7 cells was incubated in the presence of 50 ng/mL of Receptor Activator for Nuclear 356 
Factor κ B Ligand (RANKL) (R&D Systems, Bio-Techne, Madrid, Spain) to promote osteoclast 357 
differentiation. All types of cells (MC3T3-E1, RAW264.7 and RAW264.7 osteoclast precursors) 358 
cells were treated with 31.25 and 62.5 µg/mL of AG+CO-coated MX-loaded MSNs (n=8 per 359 
concentration). Non-treated cells incubated only with growth medium were considered as control 360 
(n=8). All growth media were refreshed every 48 h. These MSNs concentrations were chosen 361 
based on the microbiological susceptibility results. Cytotoxicity was tested by CytoTox 96® 362 
NonRadioactive Cytotoxicity Assay (Promega, USA) after 48 h of incubation, according to 363 
previously published methodology [52]. Cell proliferation was determined by addition of 364 
alamarBlue® solution (BIO-RAD, USA) at 10% (v/v) to the cell culture at 14 and 21 days of 365 
culture for MC3T3-E1 [53] cells or 4 days for RAW cells [54,55]. The 14-days and 21-days 366 
incubations of MC3T3-E1 allow to emulate how the cell proliferation of this type of cells would 367 
be affected upon incubation with the nanosystem as it would theoretically take place in vivo. Data 368 
were represented as relative proliferation of each treatment compared to the control, which was 369 
considered as 100% of cell proliferation. 370 
2.6. Hepatotoxicity model 371 
Seven 7-week-old male RjHan:SD - Sprague Dawley rats (Janvier Labs, Le Genest-Saint-Isle, 372 
France) were used for primary hepatocytes and Kupffer cells (KCs) isolation as previously 373 
described [56,57]. First, the liver was perfused in situ with 200 mL of Hanks’ balanced saline 374 
solution (HBSS) without Ca2+ and Mg2+ (Thermo Fisher Scientific) at 10 ml/min and 37 ºC 375 
without recirculation. The organ was then excised and inserted into a sterile plastic bag where ex 376 
situ perfusion was continued with 60 mL of 0.2% pronase (Merck, New Jersey, United States) in 377 
HBSS accompanied by 225 mL of 0.01% collagenase (Boehringer-Mannheim, Ingelheim, 378 
Germany) in HBSS under the same conditions. The liver was then separated from the perfusion 379 
device, the capsule was taken off and the tissue was divided into very small pieces. Tissue was 380 
dissociated in a mixture containing 0.03% pronase and 0.01% DNAse in 100 mL of HBSS and 381 
was incubated at 37 ºC with constant shaking for 30 minutes. Subsequently, a 125-µm nylon mesh 382 
filter was used to filter the liver homogenate removing the undigested tissue. The obtained cell 383 
suspension was centrifuged at 70×g at 4 ºC for 4 minutes. Mature hepatocytes (H) were found in 384 
the pellet while non-parenchymal cells (NPCs) were detected in the supernatant. The 385 
centrifugations were repeated two more times, and all the supernatants were collected for KCs 386 
isolation. To purify the hepatocyte population, the pellets were treated with a Percoll density-387 
gradient centrifugation (GE Healthcare, Marlborough, MA). For KCs isolation, supernatants were 388 
treated with 100 mL of HBSS supplemented with 100 μg/mL DNAse and 1% BSA, achieving 389 
their dissociation by gently shaking for 5 minutes. The cell suspension was then filtered using a 390 
297 µm nylon mesh filter and centrifuged at 500×g for 6 min at 4 ºC. To separate the KCs from 391 
other NPCs cells, the suspension was subjected to an Optiprep density gradient (Sigma-Aldrich, 392 
Missouri, United States) and centrifuged at 1,400 g for 17 minutes at 4 ºC, thus isolating the KCs. 393 
These cell co-cultures were seeded at a 2:1 ratio (H: KC) on 48-well Type-I collagen-coated 394 
plates. First, 375,000 hepatocyte cells were plated into each well and allowed to adhere for 395 
approximately 1h at 37 ºC / 5% CO2 with gentle shaking every 20 minutes. The medium was 396 
changed after hepatocytes attachment to remove unbound cells. Then, 187,500 KCs from the same 397 
donor-matched were added to each well and again the KCs were allowed to adhere for 1 h, with 398 
manual gentle shaking every 20 min. Afterward, the medium of the wells was changed for 399 
maintenance and later use. The cells were incubated with two different concentrations of AG+CO-400 
coated MX-loaded MSNs (32.25 and 62.5 µg/mL) for 1 hour. Cells incubated with 50 µM of 401 
trovaflaxacin (TVX) (Sigma Aldrich, Missouri, United States) plus 1 µg/mL lipopolysaccharide 402 
(LPS) (Sigma Aldrich, Missouri, United States) were used as positive control. The supernatant of 403 
each condition was then collected and stored at -80 ºC until the time of analysis. The levels of 404 
each cytokine were measured using rat TNF-α and IL-6 ELISA kits according to the 405 
manufacturer's recommendations (Life Technologies, Thermo Fisher Scientific, Massachustts, 406 
United States) and quantified using a Synergy™ HTX Multi-Mode Microplate Reader (Biotek, 407 
Vermont, USA). Cyp3A activity was measured directly in cells in each well by using the P450-408 
Glo ™ CYP3A4 assay with Luciferin-IPA (Promega, Wisconsin, United States) according to the 409 
indications for cultured cells, and using a luciferin standard curve (Luciferin Beetle, Promega). 410 
Samples were analyzed using a Synergy™ HTX Multi-Mode Microplate Reader. 411 
2.7. In vivo model 412 
This study was approved by the Instituto de Investigación Sanitaria of Fundación Jiménez Díaz 413 
(IIS-FJD) Animal Care and Use Committee, which includes ad hoc members for ethical issues. 414 
Animal care and maintenance complied with institutional guidelines as defined in national and 415 
international laws and policies (Spanish Royal Decree 53/2013, authorization reference 416 
PROEX109.7/21 July 18, 2021, by the Ministry of the Environment, Local Administration and 417 
Territorial Planning of the Community of Madrid and, Directive 2010/63/EU of the European 418 
Parliament and of the Council of September 22, 2010). 419 
Specific pathogen free New Zealand white male rabbits (Granja San Bernardo, Navarra, Spain) 420 
of between 2.5 and 3 Kg of weight were used. All animals were housed in individual cages in an 421 
air-conditioned room at 22±2ºC and light-darkness cycles of 12:12 h. 422 
2.7.1. Evaluation of systemic administration 423 
Three rabbits were treated under general anaesthesia with an intravenous injection through the 424 
marginal vein of the left ear of 62.5 µg of AG+CO-coated MX-loaded MSNs per millilitre of 425 
rabbit blood, considering that each animal possesses 66.33 mL of blood per kilogram [58]. Two 426 
days after the intravenous treatment, each animal was euthanized under general anaesthesia by 427 
intracardiac overdose of sodium thiobarbital. The rabbit spleen, liver and a kidney were recovered 428 
through sterile preparation, surgical field isolation. All organs were fixed, paraffin-infiltrated, and 429 
haematoxylin-eosin stained. 430 
2.7.2. Osteomyelitis model 431 
The E. coli ATCC25923-GFP strain was employed for this in vivo model. Each animal was placed 432 
in the supine position under general anaesthesia, its hind leg was immobilised and isolated in a 433 
sterile field. Skin and muscles were sectioned until the lateral epicondyle was reached (Figure 1a-434 
b). A hole 3.2 mm in diameter and 1 cm deep was drilled. A 5-mm-long and 3-mm-diameter 435 
cylindrical Ti-6Al-4V implant infected with E. coli was placed (Figure 1c). Each implant was 436 
incubated with 2 mL of a 3 McFarland suspension of E. coli (≈2.58×108 colony-forming units 437 
per millilitre) in a well from a 12-well plate for 2 h at 37°C and 5% CO2 for implant infection. 438 
After incubation, each implant was washed with 2 mL of saline (B. Braun, Germany). After 439 
lodging the infected implant in the bone marrow, the hole was closed with Ethicon bone wax 440 
(Johnson & Johnson, United States) (Figure 1d). The entire area was disinfected with 6-volume 441 
hydrogen peroxide. The wound was closed with a continuous cross suture using a 3/0 Prolene 442 
suture (Johnson & Johnson, United States) (Figure 1e). The correct location of the implant was 443 
corroborated through dorsoventral (Figure 1f) and lateral (Figure 1g) fluoroscopy of each animal. 444 
The behaviour, temperature and weight of each animal were monitored every 24 h throughout the 445 
experimental procedure. 446 
The infected animals were randomly assigned to two groups, namely control group (n=3) and 447 
AG+CO-coated MX-loaded MSNs treated group (n=3).  The sample size was estimated by 448 
Wilcoxon Mann-Whitney test and an a-priori type of power analysis considering d=4.00, α=0.05, 449 
(1-β)=0.95, allocation ratio=1 by using G*Power 3.1.9.7 software [59]. The d parameter assumes 450 
that AG+CO-coated MX-loaded MSNs treatment can reduce the bacterial concentration by at 451 
least 99% per gram of bone when compared to the uncoated implant group. The statistical power 452 
of the sample was 0.983. 453 
Three days after the surgery, each animal was anaesthetized and treated with a 4-mL intraosseous 454 
injection of 62.5 µg/mL of AG+CO-coated MX-loaded MSNs by using a 1.5-cm needle and 455 
Arrow® EZ-IO® Intraosseous Vascular Access System (Teleplex, Ireland) (Figure 2). The 456 
control group received no treatment. Two days after the intraosseous treatment, all animals were 457 
euthanized under general anesthesia by intracardiac overdose of sodium thiobarbital. The rabbit 458 
femur, liver and a kidney were recovered through sterile preparation. 459 
For microbiological studies, each femur with the implant was smashed with a hammer. This 460 
smash was immersed in sterile saline and sonicated using an Ultrasons-H 3000840 low-power 461 
bath sonicator (J. P. Selecta, Barcelona, Spain) at 22ºC for 5 min [50]. The resulting sonicate was 462 
diluted in a 10-fold dilution bank and seeded on blood-chocolate agar (Biomérieux, Marcy-463 
l'Étoile, France) using the spread plate method [60,61]. The concentration of bacteria was 464 
estimated as CFU/g of bone and adnexa. The liver and one kidney of each animal were intended 465 
for pathological studies. Histological sections were fixed, paraffin-infiltrated, and hematoxylin-466 
eosin stained. 467 
2.8. Statistical analysis 468 
Statistical analyses were performed using Stata Statistical Software, Release 11 (StataCorp 2009). 469 
Data were evaluated using a one-sided Wilcoxon nonparametric test to compare two groups. 470 
Statistical significance was set at p-values ≤0.05. All results are represented as median and 471 
interquartile range. 472 
3. Results 473 
3.1. Nanoparticles characterization 474 
3.1.1. Synthesis and functionalization of mesoporous silica nanoparticles 475 
The successful coating with AG and CO was confirmed through different characterization 476 
techniques (Figure 3 and Figure S2). TGA (Figure 3a) showed a difference in a weight loss of 8% 477 
and 14% for AG-coated MSNs and AG+CO-coated MSNs, respectively, compared to pristine 478 
MSNs. Hence, it could be concluded that the amount of CO adsorbed onto the surface was ca. 479 
6%. The presence of AG and CO was further confirmed through FTIR spectroscopy (Figure 3b). 480 
In this regard, the appearance of a deep vibration band at ca. 3400 cm-1 (νOH) as well as a subtle 481 
one at ca. 3000 cm-1 (νCH) in the AG-coated MSNs spectrum were ascribed to the presence of AG. 482 
This was in agreement with the vibration bands observed for AG alone (Figure S3). Finally, the 483 
presence of vibrations bands at 1650 and 1540 cm-1 that were ascribed to the amide bonds of CO 484 
undoubtedly confirmed its successful adsorption onto the surface. Besides, AG+CO-coated MSNs 485 
were stained with phosphotungstic acid and observed under the TEM, where the blurry surface 486 
was indicative of organic matter deposition (Figure 3c). Zeta potential measurements on AG+CO-487 
coated MSNs yielded a value of -21.6 mV, which was less negative than what observed for MSNs 488 
(-34.8 mV), in agreement with the presence of free amino groups throughout the structure of CO. 489 
Finally, the colloidal stability of different nanoparticles was analysed through DLS 490 
measurements, yielding a size distribution centred at 190 nm (Figure S2). In this sense, the 491 
stability of nanoparticles remained unaffected by different functionalizations, highlighting their 492 
suitability for biomedical applications.  493 
3.1.2. Antibiotic release from MSNs 494 
MX release from the different nanomaterials was evaluated in vial. As shown in Figure 3d, 495 
modifying the surface with a macromolecule with affinity for the biofilm, AG, and a high 496 
molecular weight antibiotic, CO, led to release kinetics similar to that observed for MSNs. The 497 
different release data shown in Figure 3d were fitted to a first-order kinetic model with an 498 
empirical nonideality factor (δ) (Equation 1) [62,63]:  499 
Y = A(1-e-kt)δ                                   (1) 500 
Where Y is the percentage of MX released at time t, A the maximum amount of MX released (in 501 
percentage), and k, the release rate constant. The obtained values are summarized in Figure 3d.  502 
On the other hand, the release profile of CO-FITC+AG-coated MSNs (Figure 3e) demonstrated 503 
that the AG coating enhanced the amount of CO loaded onto the surface, which could be 504 
beneficial for the biological studies, as it would reduce the need to use high doses of this 505 
nanomedicine.  506 
3.2. Microbiological studies 507 
3.2.1. Bacteria-nanoparticle interaction 508 
AG-coated MSNs were incubated with E. coli to evaluate whether the polymeric coating could 509 
be effectively degraded into its monomers by such enzymes and be employed as a carbon source 510 
by the bacteria. As shown in Figure 4a, E. coli concentration showed more than two-fold increase 511 
in the presence of AG-coated MSNs compared to pristine MSNs (p-value<0.0001). The 512 
enzymatic degradation of AG was further confirmed through a release experiment. For that 513 
purpose, MSNs and AG-coated MSNs were placed with bacteria to evaluate whether the enzyme-514 
mediated degradation of AG affected the release profile (Figure 4b). In contrast to Figure 1d, the 515 
PI release was almost equal from MSNs and AG-coated MSNs in presence of E. coli. The 516 
different nanoparticles were then faced to an E. coli mature biofilm and left to interact for 30 min. 517 
As observed in Figure 4c, the highest retention values were observed for both AG- and AG+CO-518 
coated MSNs, showing the latter slightly more accumulation (p<0.0307). However, the analysis 519 
of the interaction at 3 h demonstrated that AG-coated MSNs maintained its high retention 520 
capability, whereas that of AG+CO-coated MSNs significantly decreased, equalling the results 521 
obtained for pristine MSNs. 522 
AG+CO-coated MSNs significantly reduced the E. coli viability (p-value=0.0143) compared to 523 
AG-coated MSNs and pristine MSNs (by 42% and 41%, respectively) (Figure 4d). These results 524 
were confirmed by using TEM (Figure 5), which allowed to inspect visually the physical changes 525 
induced by the drug-loaded nanoparticles on the bacteria. Bacteria faced to pristine MSNs and 526 
AG-coated MSNs showed a normal appearance, with an intact outer membrane and bacterial wall 527 
intimately linked to the cytoplasm (Figure 5a-d). In some cases, AG-coated MSNs were intimately 528 
in contact with the outer membrane of some bacteria (Figure 5d). The interaction between E. coli 529 
and AG+CO-coated MSNs gave rise to the presence of vacuoles inside the bacteria (Figure 5e-f) 530 
resulting from the detachment of the cytoplasmic membrane from the cell wall right where the 531 
bacterium had interacted with an AG+CO-coated MSN, which was unequivocally ascribed to 532 
bacterial death (Figure 5f).  533 
3.2.2. Minimal inhibitory concentration (MIC), minimal bactericidal concentration 534 
(MBC), minimal biofilm inhibitory concentration (MBIC), and minimal biofilm 535 
eradication concentration (MBEC) 536 
The antibacterial effect of the nanoparticles was evaluated by studying the MIC and MBC. For 537 
that purpose, different nanoparticles were faced against planktonic E. coli at different 538 
concentrations. The MIC and MBC of MX against E. coli were found to be <0.0625 µg/mL for 539 
both. The MIC and MBC of CO against E. coli were found to be 2 µg/mL for both. The MIC and 540 
MBC of MX-loaded MSNs against E. coli were found to be <1.953 µg/mL for both. The MIC 541 
and MBC of CO-coated MSNs against E. coli were found to be 15.625 µg/mL for both. Finally, 542 
the MIC and MBC of AG+CO-coated MX-loaded MSNs against E. coli were found to be 1.953 543 
and 3.906 µg/mL, respectively. 544 
The antibiofilm effect of nanoparticles was evaluated by studying the MBIC and MBEC. For that, 545 
different nanoparticles were faced against an E. coli biofilm at different concentrations. The 546 
MBIC and MBEC of MX against E. coli was found to be <0.0625 and 1 µg/mL, respectively. The 547 
MBIC and MBEC of CO against E. coli were found to be 64 and 128 µg/mL, respectively. The 548 
MBIC and MBEC of MX-loaded MSNs against E. coli were found to be 1.953 and 15.625 µg/mL, 549 
respectively. The MBIC and MBEC of AG+CO-coated MSNs against E. coli were found to be 550 
2,000 and >2,000 µg/mL, respectively. Finally, the MBIC and MBEC of AG+CO-coated MX-551 
loaded MSNs against E. coli were found to be 1.953 and 7.813 µg/mL, respectively. 552 
3.2.3. Anti-biofilm efficacy of AG+CO-coated MX-loaded MSNs 553 
Bearing in mind the above-described results, and an in vitro model of infected bone was 554 
developed for the subsequent preparation of in vivo experiment. For that purpose, two 555 
concentrations of AG+CO-coated MX-loaded MSNs, 31.25 (4×MBEC) and 62.5 µg/mL 556 
(8×MBEC), were chosen to be used against E. coli. Both concentrations of AG+CO-coated MX-557 
loaded MSNs were able to decrease more than 99.9% the viability of biofilm grown on the 558 
trabecular bone compared to non-treated biofilm (p-value<0.01) (Figure 6a). Furthermore, the 559 
62.5-µg/mL concentration significantly reduced 98.9% more bacteria than 31.25-µg/mL 560 
concentration (p-value=0.0238). To support these numerical results, representative images from 561 
each treatment were taken (Figure 6b-i). Non-treated E. coli biofilm showed many different small 562 
viable aggregates of bacteria or microcolonies mainly adhered on the bone surface (Figure 6b-c), 563 
an aspect that is reminiscent of the microscopic appearance of certain biofilms isolated from 564 
clinical samples [64]. When E. coli biofilm was exposed to 31.25 µg/mL, the number of 565 
aggregates was slightly lower (Figure 6d-f).  In this case, AG+CO-coated MX-loaded MSNs 566 
adhered on microcolonies. This MSNs attachment would be responsible for the absence of viable 567 
bacteria (absence of green fluorescence) in the periphery of microcolonies (Figure 6d-f). The best 568 
results were obtained when the E. coli biofilm was treated with 62.5 µg/mL of AG+CO-coated 569 
MX-loaded MSNs (Figure 6g-h). As shown in Figure 4g, the quantity of viable bacteria into the 570 
microcolonies adhered on the bone surface was extremely scarce. Likewise, AG+CO-coated MX-571 
loaded MSNs adhered on those few aggregates, but the viable bacteria inside of them were fewer 572 
than those in the microcolonies treated with 31.25 µg/mL (Figure 6h-i). At microscopic level 573 
(Figure 7), untreated E. coli biofilm grown on bone showed  bacterial clusters adhered on bone 574 
and was embedded in exopolymeric substances (Figure 7a-c), in opposition to the E. coli cells 575 
observed on the bone surface treated with 32.5 and 61.25 µg/mL (Figure 7d-f) which were found 576 
in the form of aggregates, mainly 32.5 µg/mL, or simply as individualized cells completely 577 
covered by the nanoparticles and displaying important membrane damages, mainly 61.25 µg/mL 578 
(Figure 7g-i). 579 
3.3. Cell studies 580 
The biocompatibility of AG+CO-coated MX-loaded MSNs was evaluated on bone-related cells 581 
(Figure 8). AG+CO-coated MX-loaded were found to be non-cytotoxic for osteoclasts, and only 582 
reduced cytotoxicity was observed at the highest concentration (62.5 µg/mL) for osteoblasts and 583 
macrophages. Moreover, AG+CO-coated MX-loaded MSNs had an impact on the cell 584 
proliferation of osteoblast and macrophages (Figures 9a, 9c), since these cells decreased their 585 
proliferation in presence of nanoparticles. Interestingly, osteoblast showed a dose-dependent 586 
effect on proliferation at 14 days, but these cells showed better proliferation in presence of 62.5 587 
µg/mL than 31.25 µg/mL at 21 days (Figure 9a). 588 
3.4.  Hepatotoxicity model 589 
The results derived from the hepatotoxicity model are shown in Figure 10. Tumor necrosis factor-590 
α (TNF-α) increased proportionally with the concentration of AG+CO-loaded MX-loaded MSNs 591 
(Figure 10a), whereas interleukin-6 (IL-6) showed opposite behaviour (Figure 10b). In addition, 592 
cytochrome P450 metabolic capacity (CYP3A) decreased proportionally with the concentration of 593 
nanoparticles (Figure 10c). 594 
In vivo studies 595 
3.4.1. Evaluation of systemic administration 596 
The three livers showed a preserved hepatic parenchyma architecture with absence of hepatocyte 597 
lesion. In one of the animals, mild intraepithelial lymphocytosis in the ducts and presence of 598 
chronic central perivenular inflammatory aggregates were identified. In the remaining two, mild 599 
signs of ductulitis were observed, with signs of lymphocytosis in bile ducts (Figure 11a-b). The 600 
three kidneys showed a renal parenchyma with normal morphology and appearance without 601 
glomerular or tubular lesions, and absence of inflammation or necrosis (Figure 11c-d).  The three 602 
spleens showed a splenic pulp without relevant microscopic alterations (Figure 11e-f). 603 
3.4.2. Osteomyelitis model 604 
AG+CO-coated MX-loaded MSNs completely eradicated E. coli infection in two out of the three 605 
treated femurs and reduced up to 99.4% in the remaining femur, compared to the control group 606 
(Figure 12).  607 
 608 
The three livers of control (untreated) group showed liver parenchyma with mild-moderate central 609 
perivenous portal inflammation and minimal lobular hepatitis (Figure 13a-b). The inflammatory 610 
infiltrate consisted of lymphocytes, plasma cells and eosinophils (Figure 13c). The livers of 611 
AG+CO-coated MX-loaded MSNs-treated group showed liver parenchyma with preserved 612 
cytoarchitecture without hepatocyte lesions (Figure 13d). Minimal foci of ductulitis with signs of 613 
lymphocytes in bile ducts were observed in all three treated animals (Figure 13e-f). Focal signs 614 
of cholestasis were detected in one of the treated rabbits. All the kidneys from both control group 615 
and AG+CO-coated MX-loaded MSNs-treated showed renal parenchyma of normal morphology 616 
and appearance without glomerular or tubular lesions, and absence of inflammation or necrosis. 617 
4. Discussion 618 
In this study, we demonstrate the feasibility of using AG+CO-coated MX-loaded nanoparticles 619 
to treat bone infections caused by E. coli, showing no cytotoxicity on osteoblast, osteoclast and 620 
macrophages in vitro, and absence of organ damage in vivo upon intraosseous administration. 621 
Given the bacterial origin of this kind of infection, two clinically relevant antibiotics, MX and 622 
CO, were selected as cargos. Because of its low molecular weight (401 g/mol), MX would be 623 
easily loaded within the mesoporous of nanoparticles, as previously reported [65,66]. Conversely, 624 
CO would be likely adsorbed onto the surface of nanoparticles, as previously stated for other 625 
polymixins and MSNs [32,67,68].  626 
The MX release was monitored and fitted to a first-order kinetic model (Figure 1d). In this model, 627 
the values for δ are comprised between 0, for materials that release the drug at the very beginning 628 
of the experiment, and 1, for materials that follow the first-order kinetics. According to Figure 629 
1d, the δ values estimated for the different nanoparticles were closer to 0, in agreement with the 630 
pronounced burst effect observed during the initial hour. This kinetics has also been observed for 631 
other antibiotics loaded in mesoporous silica-based nanoparticles [69]. Also, δMSNs was 632 
comparatively lower than those of coated samples, which would account for the slight differences 633 
observed among them during release experiments. Considering these results, the AG+CO-coated 634 
MSNs would be able to release large amounts of MX in a short time, thereby achieving high local 635 
concentration of antibiotics nearby bacteria from a low quantity of nanoparticles, which might 636 
reduce the potential side effects associated with other administration routes. 637 
Even though CO might have been simply adsorbed on the surface of particles and directly used 638 
against bacteria, our results indicate that incorporating CO along with the AG coating was 639 
beneficial to enhance the final amount of this antibiotic on nanoparticles (Figure 1e). We 640 
hypothesize that the reason behind this result would be that AG can act as a polymeric mesh that 641 
would favour the retention of CO on nanoparticles during the washing steps, resulting in a 642 
significantly higher final amount of antibiotic loaded. Hence, although the synergetic effect of the 643 
use of polimixins plus another antibiotic has been previously reported [32]. This work 644 
demonstrates that the use of Arabic gum improves the adsorption capacity of nanoparticles, 645 
potentially diminishing the final nanoparticle dose that would be required during the treatment if 646 
CO alone was to be used. 647 
AG, a branched-chain, complex polysaccharide composed of 1,3-linked beta-D-galactopyranosyl 648 
monomers connected to the main chain through 1,6-linkages [27], can be degraded by the 649 
enzymatic battery of enterobacteria [70–72]. In this sense, our results (Figure 2a) confirmed that 650 
AG coating can be degraded by E. coli enzymes into galactopyranose monomers that are used as 651 
a carbon source [30,31]. This finding points out that AG lacks antibacterial capacity per se, unlike 652 
other gums such as Iranian gum do [73]. That enzymatic degradation of AG was further confirmed 653 
through a PI release experiment (Figure 2b), in which almost equal amount of PI was released 654 
from MSNs and AG-coated MSNs in presence of E. coli, demonstrating that E. coli metabolically 655 
active cells can degrade the AG coating while the bacterium grows. The interaction between E. 656 
coli mature biofilm and different nanoparticles (Figure 2c) brought out that AG-coated MSNs 657 
showed a higher accumulation that non-coated ones at short time (30 min). Interestingly, 658 
AG+CO-coated MSNs showed a slight but significantly higher accumulation than AG-coated 659 
MSNs. However, setting the incubation period at 3 h revealed that AG-coated MSNs maintained 660 
its high accumulation capability to biofilm, whereas that of AG+CO-coated MSNs matched that 661 
of pristine MSNs.  Thus, our results would indicate that functionalizing the surface of MSNs with 662 
AG increased the targeting ability of nanoparticles for E. coli infectious foci. This enhanced 663 
accumulation might be the result of the biomatrix accumulation of enzymes [74] able to cleave 664 
the polymeric chains of AG, e.g. β-galactosidase [75]. This enzymatic cleavage would favour the 665 
retention of nanoparticles to biofilm matrix at very short times and would made the AG coating a 666 
specific coating for E. coli and other enterobacteria that secrete these enzymes [76]. After this 667 
accumulation, the colistin carried by the AG-coated MSNs would be released and exert a 668 
destabilising effect on the E. coli biofilm matrix structure [77]. To the best of our knowledge, this 669 
is the first study that uses a gum of natural origin as a targeting agent for a specific bacterial 670 
pathogen. Overall, gums of different origin are worth being explored as there are already few 671 
examples of their potential in nanomedicine. For instance, it has been reported that Guar gum can 672 
be used as targeting agent for colorectal cancer treatment [78–81]. Similarly, Iranian gum has 673 
been shown to present antimicrobial properties per se and has been used for wound healing 674 
applications [73]. Besides, these gums have been recently incorporated into hydrogels that show 675 
unique advantages compared to other polymeric materials, and find application as periodontal 676 
materials, drug carriers, bone matrices [82–85], and artificial blood vessels fabricated by 3D 677 
printing [86]. Some of those hydrogels, as those composed of Arabic gum, gelatin plus 678 
polyurethane [87], or those containing N‑O‑carboxymethyl chitosan [88] have been also used for 679 
wound healing applications and wound infection prevention.    680 
It is known that CO kills Gram-negative bacteria throughout five mechanisms: (1) disruption of 681 
the bacterial outer and inner membranes, (2) vesicle-vesicle contact pathway, (3) hydroxyl radical 682 
death pathway, (4) inhibition of respiratory enzymes, and (5) anti-endotoxin colistin activity [89]. 683 
Any of these mechanisms would be responsible for the bactericidal effect observed in AG+CO-684 
coated MSNs at short term (30 min) against the planktonic state of E. coli. These results were 685 
further supported by TEM study, where the presence of vacuoles resulting from the detachment 686 
of the cytoplasmic membrane from the cell wall [90] was only detected in the bacteria exposed to 687 
AG+CO-coated MSNs . 688 
The antibacterial effect of nanoparticles was evaluated by MIC and MBC. According to the results 689 
obtained, E. coli ATCC 25922-GFP is susceptible to MX (<1 µg/mL) [91] and CO (≤2 µg/mL) 690 
[92]. In consequence, the combined use of both antibiotics seems highly appropriate for achieving 691 
outstanding therapeutic effect against E. coli ATCC25922GFP. On the other hand, the antibiofilm 692 
effect of nanoparticles was evaluated by MBIC and MBEC. For that purpose, different 693 
nanoparticles were faced against an E. coli biofilm at different concentrations, resulting the MBIC 694 
and MBEC of AG+CO-coated MX-loaded MSNs against E. coli 1.953 and 7.813 µg/mL, 695 
respectively. In light of these results, MX would be a possible treatment for E. coli biofilm, as 696 
recommended by other authors [93,94]. Despite CO was shown to be ineffective in inhibiting and 697 
eradicating the E. coli biofilm, the actual role of this antibiotic in the potential treatment of 698 
osteomyelitis will be discussed later. 699 
Given the promising results, the antibacterial efficacy of AG+CO-coated MX-loaded MSNs in a 700 
more realistic scenario was studied by using an in vitro model of bacterial biofilm grown in 701 
wound-like medium [40,41] on bovine trabecular bone. The highest concentration of AG+CO-702 
coated MX-loaded MSNs (62.5 µg/mL; 8×MBEC) was the most effective against E. coli biofilm. 703 
The main differences between two concentrations were (1) the bacterial viability and (2) the 704 
quantity of microcolonies adhered on the bone (Figure S4). The bacterial viability reduction was 705 
a consequence of the MX released from loaded nanoparticles, as this antibiotic is a fourth-706 
generation broad-spectrum fluoroquinolone that is highly effective against biofilm-related 707 
infection [95–97]. In addition, this antibiotic is a recent fluoquinolone and has been seldom used 708 
in the antibiotic-loaded nanoparticle field, where the main fluoroquinolone used is levofloxacin 709 
[98–101]. The reduction of the quantity of microcolonies adhered on the bone surface was directly 710 
related to the CO contained in AG coating of the surface of nanoparticles, since this antibiotic has 711 
a destabilising effect on E. coli biofilm matrix structure and it can lead to the release of planktonic 712 
cells, which are more susceptible to antibiotics [77]. Hence, the use of AG+CO-coated MX-713 
loaded MSNs showed a cooperative effect between both antibiotics, confirming the suitability of 714 
using this nanocarrier for the treatment of bone infections caused by E. coli. 715 
Bone infections are linked with progressive inflammatory tissue destruction and can induce 716 
marked local bone resorption at sites of infection and proximal abnormal bone formation. Overall, 717 
three types of cells are responsible for this process, namely osteoblasts/osteocytes, osteoclast and 718 
macrophages, although others can be involved [102]. Nevertheless, the lowest cytotoxicity 719 
median value was ranged between 93.5% for 31.25 µg/mL and 94.54% for 62.5 µg/mL, which 720 
can be considered as low for all types of cells used according to previously published studies 721 
[103]. The reduction of cell proliferation would be a consequence of two antibiotics used, CO and 722 
MX, as observed in both osteoblasts (at 14 days) and macrophages. CO can inhibit cell 723 
proliferation in a dose-dependent and time-dependent manner [104], whilst MX has shown an 724 
antiproliferative effect on certain cells [105], as reported previously by other authors that used 725 
moxifloxacin as cargo in sol-gel-based materials [106]. In this sense, the use of nanoparticles to 726 
deliver these antibiotics would imply the administration of lower doses and the decrease of their 727 
side effects [107–110]. Hence, our treatment would entail a transient antiproliferative effect for 728 
the sake of an effective anti-bacterial benefit in the treatment of bone infections. It is noteworthy 729 
that osteoblasts exposed to the higher dose (62.5 µg/mL) showed  superior proliferation at 21 days 730 
than those exposed to the lower dose (31.25 µg/mL). We hypothesize that this behaviour might 731 
stem from the Arabic gum coating of the MSNs, which might favour the osteoblastic proliferation 732 
in the long term. This would be in agreement with the finding that gum tragacanth can promote 733 
the adhesion, proliferation, and osteogenic differentiation of adipose-derived mesenchymal stem 734 
cells [111]. 735 
MSNs tend to accumulate in the reticuloendothelial system, which consists of cells descending 736 
from the monocytes able to perform phagocytosis of foreign materials [112]. Up to 90% of the 737 
reticuloendothelial system is located in the liver [113]. Hepatic reticuloendothelial system 738 
includes endothelial cells, Kupffer cells (KCs), fat storing cells and pit cells [114].  KCs have 739 
special surface structures responsible for the phagocytotic capacity, the so-called fuzzy coat [114]. 740 
This phagocytic activity can cause their activation and the production of a number of cell signaling 741 
and stress pathway modulators, e.g. reactive oxygen species and cytokines such as TNF)-α [57]. 742 
This factor promotes the synthesis of interleukin 6 (IL-6) both in KC and in endothelial cells and 743 
in liver stelae, which is a cytokine involved in the proliferation of hepatocyte cells [115]. 744 
Cytochrome P450 3A (CYP3A) is an enzyme mainly found in the liver and in the intestine able 745 
to oxidize small foreign organic molecules, such as toxins or drugs [116]. Due to the role of the 746 
liver on systemic administration of MSNs, we decided to evaluate the hepatotoxicity of our 747 
nanosystem on a hepatocyte-KCs co-culture model. As shown in Figure 10, AG+CO-coated MX-748 
loaded MSNs provoked a statistically significant increase of TNF-α concentration and a 749 
significant decrease of IL-6 concentration. An increase in TNF-α precedes the onset of hepatic 750 
parenchymal cell injury [117], that, in this scenario, could be reflected on the reduced IL-6 751 
production by KCs and hepatic CYP3A activity. Even though there are up to three Kupffer cell-752 
mediated clearance pathways of MSNs (endocytosis, phagocytosis, and micropinocytosis) [118], 753 
AG+CO-coated MX-loaded MSNs uptake by KCs was not observed in hepatocyte-KCs co-754 
culture (data not shown). Thus, the hepatoxicity associated to AG+CO-coated MX-loaded MSNs 755 
observed in our results might be due to the effect of the high amount of colistin loaded by AG+CO 756 
coating, hepatotoxicity  that has already been described in a patient with Gram-negative rod 757 
bacteremia treated intramuscularly with colistin [119]. This hypothesis derived from the in vitro 758 
hepatic model would be further supported by the pathological findings on the livers of the rabbits 759 
that received a single intravenous dose of nanoparticles, which showed mild signs of ductulitis 760 
with signs of lymphocytosis in bile ducts (Figure 11). This would point out that these 761 
nanoparticles could cross the endothelium into the Disse space, from where they could be slowly 762 
returned to lymphatic circulation, taken up by hepatocytes or subsequently involved in a biliary 763 
excretion pathway [118]. This transient passage through the liver parenchyma would be favoured 764 
by the size of AG+CO-coated MX-loaded MSNs (~190 nm), which is within the range of the 765 
fenestration diameter (100-200 nm) of the endothelium of hepatic sinusoid [120], and would be 766 
slow enough to result in local lymphocytosis around the bile ducts. This finding would vouch the 767 
use of local (specifically intraosseous), rather than systemic, administration of nanoparticles. The 768 
rationale behind this benefit can be explained as follows. Rapid bloodstream clearance of 769 
nanoparticles after intravenous administration has long been recognized as a major barrier to drug 770 
delivery [121]. In this sense, it has been recently discovered that administering a dose that 771 
surpasses the maximum Kupffer cell uptake rate significantly diminishes the proportion of 772 
nanoparticles taken up by the reticuloendothelial system [122]. In consequence, maintaining a 773 
significant dose in the blood would imply the need to administer a rather large dose of 774 
nanoparticles, which would inherently yield higher hepatic damage. Conversely, injecting the 775 
nanoparticles in a localized manner allows to achieve high drug concentration right at the 776 
infection site by using a significantly lower quantity of nanoparticles. Hence, this approach would 777 
diminish the potential organ damage owing to the lower dose injected. 778 
As observed in Figure 12, AG+CO-coated MX-loaded MSNs treatment was able to eradicate 779 
completely the osteomyelitis provoked by E. coli in two out of three rabbit and to reduce the 780 
bacterial concentration more than 99% in the remaining animal. The pathological findings also 781 
supported the microbiological results. The livers of control group showed a mild-moderate central 782 
perivenous portal inflammation and minimal lobular hepatitis accompanied by an inflammatory 783 
infiltrate consisting of lymphocytes, plasma cells and eosinophils, a suggestive indicator of an 784 
infectious process in the animal [123]; the liver of treated rabbits just showed the same 785 
histological signs derived from the intraosseous administration of AG+CO-coated MX-loaded 786 
MSNs that will inevitably end up reaching the systemic circulation and being taken up by the 787 
liver, except that it will do so later and in lower concentration than if administered intravenously. 788 
In light of our results, AG+CO-coated MX-loaded MSNs arise as a novel strategy for the localized 789 
treatment of bone infections, involving minimal recruitment of the reticuloendothelial organs (e.g. 790 
liver and kidneys). Indeed, this nanoformulation could be incorporated or combined with existing 791 
ones, including, antibiotic-loaded collagen sponges [124], bone cements [125], or new treatment 792 
approaches, e.g. hydrogels [126,127], polymers [128], or microplates [129]. 793 
This study is not exempt from limitations. First, despite Gram-negative bacteria suppose an 794 
increasing threat to bone-associated infections, they still represent a reduced percentage of all 795 
these infections. In this regard, the rationale behind our therapeutic approach could be employed 796 
for the development of a similar nanosystem specifically designed for the treatment of Gram-797 
positive infection related to bone. Second, E. coli stands out among the Gram-negative 798 
bacteria for their ability to develop antibiotic resistance. For that reason, we considered it 799 
a reasonable bacterial model to test our nanosystem, although more additional Gram-800 
negative bacteria relevant to osteomyelitis, e.g., Pseudomonas aeruginosa, should be 801 
further evaluated. Furthermore, moxifloxacin has been employed here as an example 802 
antibiotic loadable in MSNs. However, because quinolone resistance is increasing 803 
worldwide [130], these nanoparticles might be specifically loaded with alternative 804 
fluoroquinolones or other antibiotics according to the geographic prevalence of antibiotic 805 
resistance to ensure good infection outcome.  806 
5. Conclusions 807 
In this work, moxifloxacin-loaded mesoporous silica nanoparticles have been successfully 808 
functionalized with Arabic gum plus colistin (AG+CO-coated MX-loaded MSNs) to be employed 809 
in the treatment of bone infections cause by E. coli. The nanosystem demonstrated high affinity 810 
toward E. coli biofilm matrix, thanks to AG coating, and marked antibacterial effect because of 811 
the bactericidal effect of moxifloxacin and the disaggregating effect of colistin. AG+CO-coated 812 
MX-loaded MSNs were able to eradicate the infection developed on a trabecular bone in vitro 813 
and showed pronounced antibacterial efficacy in vivo against an osteomyelitis provoked by E. 814 
coli. Furthermore, AG+CO-coated MX-loaded MSNs were shown to be essentially non-cytotoxic 815 
with only slight effect on cell proliferation and mild hepatotoxicity, which might be attributed to 816 
the nature of both antibiotics. In view of these results, these nanoparticles may be considered as 817 
a promising treatment for bone infections caused by enterobacteria, such as E. coli, and introduce 818 
a general strategy against bone infections based on the implementation of antibiotics with 819 
different but complementary activity into a single nanocarrier. 820 
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  1290 
Figures 1291 
 1292 
Scheme 1. Mesoporous silica nanoparticles (green) loaded with moxifloxacin (yellow) (a) and 1293 
coated with Arabic gum (purple) plus colistin (blue). 1294 
 1295 
Figure 1. Surgical model. Skin and muscles were sectioned until the lateral epicondyle was 1296 
reached (Figure 1a-b). A hole 3.2 mm in diameter was drilled and cylindrical Ti-6Al-4V 1297 
implant infected with E. coli ATCC25922GFP was placed (Figure 1c). The infected implant 1298 
was placed in the bone marrow; the hole was closed with bone wax (Figure 1d). The wound 1299 
was closed with a continuous cross suture (Figure 1e). The correct location of the implant 1300 
was corroborated through dorsoventral (Figure 1f) and lateral (Figure 1g) fluoroscopy of 1301 
each animal. The white bars represent approximately 2 cm.  1302 
 1303 
Figure 2. AG+CO-coated MX-loaded MSNs intraosseous treatment. Under general anaesthesia, 1304 
the femur of each rabbit from the treated group was drilled with a with a 1.5-cm needle (a).  1305 
The vacuum was made on the needle using drops of sterile serum (b). Finally, 4-mL of 62.5 1306 
µg/mL of AG+CO-coated MX-loaded MSNs were injected.  1307 
 1308 
Figure 3. Physico-chemical characterization of the different nanoparticles. (a) 1309 
Thermogravimetric analysis, (b) FTIR spectroscopy, (c) TEM image of phosphotungstic 1310 
acid-stained AG+CO-coated MSNs, (d) MX release experiment from MSNs (black), AG-1311 
coated MSNs (green) and AG+CO-coated MSNs (red), (e) CO-FITC release experiment 1312 
from CO-coated MSNs (black) and AG+CO-coated MSNs (red). 1313 
 1314 
Figure 4. E. coli-AG-coated MSNs interaction. (a) Use of AG-coated MSNs by E. coli as a carbon 1315 
source. (b) Propidium iodide release from MSNs (red) and AG-coated-MSNs (purple) in 1316 
presence of E. coli that is actively replicating (green). (c) E. coli biofilm- AG-coated MSNs 1317 
interaction. (d) E. coli planktonic cells-AG-coated MSNs interaction. FI: fluorescence 1318 
intensity. *: p-value<0.05, ****: p-value<0.0001 for Wilcoxon test.  1319 
 1320 
 1321 
Figure 5. TEM images of E. coli planktonic cells faced to MSNs (a-b), AG-coated MSNs (c-d), 1322 
and AG+CO-coated MSNs (e-f). C: cytoplasm. OM: outer membrane. ROM: ruptured outer 1323 
membrane. V: vacuole. 1324 
 1325 
Figure 6. Bacterial quantity per gram of trabecular bone after 24-h treatment with each AG+CO-1326 
coated MX-coated MSNs (a). Representative confocal images from the different conditions: 1327 
(b-c) positive control, (d-f) 31.25 µg/mL, and (g-i) 62.5 µg/mL of AG+CO-coated MX-1328 
coated MSNs. Green represents the E. coli viable bacteria, red represent the AG+CO-coated 1329 
MX-coated MSNs, and grey represent the trabecular bone surface. *: p-value<0.05, **: p-1330 




Figure 7. SEM images of E. coli biofilm grown on trabecular bone after 24-h treatment with each 1335 
AG+CO-coated MX-coated MSNs: (a-c) positive control, (d-f) 31.25 µg/mL, and (g-i) 62.5 1336 
µg/mL of AG+CO-coated MX-coated MSNs. 1337 
 1338 
Figure 8. Cytotoxicity of AG+CO-coated MX-coated MSNs concentration on MC3T3-E1 1339 
osteoblast (a), RAW264.7 osteoclast (b), and RAW264.7 macrophages (c). **: p-1340 
value<0.01, ****: p-value<0.0001 for Wilcoxon test. 1341 
 1342 
 1343 
Figure 9. Cell proliferation of MC3T3-E1 osteoblast (a), RAW264.7 osteoclast (b), and 1344 
RAW264.7 macrophages (c) in presence of each AG+CO-coated MX-loaded MSNs 1345 
concentration. *: p-value<0.05, **: p-value<0.01, ***: p-value<0.001 for Wilcoxon test. 1346 
 1347 
Figure 10. Tumor necrosis factor α (TNF-α) (a), interleukin 6 (IL-6) (b), and cytochrome 3A 1348 
metabolic capacity (c) from the rat hepatocyte-Kupffer cells co-cultive. *: p-value<0.05, **: 1349 
p-value<0.01 for Wilcoxon test. 1350 
 1351 
 1352 
Figure 11. Histological liver (a, b), kidney (c,d) and spleen (e, f) images with hematoxylin-eosin 1353 
stain  from a rabbit that received systemically one AG+CO-coated MX-loaded MSNs dose. 1354 
Black, green, and red bars represent 200, 100, and 50 µm, respectively. 1355 
 1356 
Figure 12. Quantity of E. coli in bone and adnexa. ∗p-value < 0.05 for Wilcoxon test. 1357 
 1358 
Figure 13. Histological liver images with hematoxylin-eosin stain of untreated rabbit (a-c) and 1359 
AG+CO MX-loaded MSNs-treated rabbit (d-f). Black and red bars represent 100 µm, and 1360 
50 µm, respectively. 1361 
 1362 
Figure S1. Nitrogen adsorption-desorption isotherms of pristine MSNs. Inset: pore size 1363 
distribution determined by the BJH method. The adsorption-desorption plot shows a type-1364 
IV isotherm, which is indicative of the presence of uniform cylindrical mesopores, as it was 1365 
expected for MCM-41 nanoparticles (J. Saudi Chem. Soc. 2018, 22, 405–415). The 1366 
mesoporosity was further validated by looking at the pore size distribution, which yielded a 1367 
size of ca. 2.6, i.e., in the mesoporous range according to the IUPAC (Central European 1368 
Journal of Chemistry 5(2):385-395). 1369 
 1370 
Figure S2. DLS and zeta potential analysis of the different nanomaterials synthesized in this 1371 
study. 1372 
 1373 
Figure S3. FTIR spectrum of Arabic gum.  1374 
 1375 
Figure S4. Schematic representation of the action mechanism of AG+CO-coated MX-loaded 1376 
MSNs (red). Aspect of a E. coli biofilm mainly composed by viable bacteria (green) 1377 
embebed in the biomatrix (light blue) (a). Aspect of E. coli biofilm treated with 31.25 (b) 1378 
and 62.5 µg/mL (c) of AG+CO-coated MX-loaded MSNs. Pink bacteria represent dead cells 1379 
by the MX effect. 1380 
